ID
MACK

Integral Derivatives’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Integral Derivatives’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2,390
Closed -$77K – 1484
2016
Q4 		$77K Buy
+2,390
New +$102K ﹤0.01% 1076

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Integral Derivatives's MACK Position: Q1 2017 in Review

Integral Derivatives sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2017, closing a stake of 2,390 shares — an estimated $77K sold.

Integral Derivatives first reported a position in MACK in Q4 2016 and held it in 1 quarter. The position peaked at $77K in Q4 2016. 116 funds tracked by Wall St. Rank hold MACK as of Q1 2017.

  • Integral Derivatives reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Integral Derivatives sold 2,390 Merrimack Pharmaceuticals, Inc. shares in Q1 2017, an estimated $77K.
  • Integral Derivatives first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2016 and held it in 1 quarter.
  • Integral Derivatives's Merrimack Pharmaceuticals, Inc. position peaked at $77K in Q4 2016.
  • 116 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2017.

Based on Integral Derivatives's 13F filing for Q1 2017, filed 15 May 2017.